Ascendis Pharma A/S reports results for the quarter ended in June 30 - Earnings Summary

Ascendis Pharma A/S

03/09/2024 22:39

* Ascendis Pharma A/S  ASND.OQ  reported a quarterly
adjusted loss
of €1.91​​ per share for the quarter ended June 30, higher than
the same quarter last year, when the company reported EPS of
€-2.16.  The mean expectation of thirteen analysts for the
quarter was for a loss of €1.42 per share. Wall Street expected
results to range from €-1.96 to -94 cents per share.
    * Revenue fell 24% to €36.00 million from a year ago;
analysts
expected €83.97 million. 
    * Ascendis Pharma A/S's reported EPS for the quarter was a
loss of
€1.91​.
    * The company reported a quarterly loss of $109.38 million.
    * Ascendis Pharma A/S shares had risen by 1.5% this
quarter and
gained 9.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 3.8%
in the last three months.​ 
    * In the last 30 days, three analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Ascendis Pharma
A/S is $195.00 
This summary was machine generated from LSEG data September 3 at
09:39 p.m. UTC. ​All figures in euros unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -1.42          -1.91          Missed
 Mar. 31 2024      -1.50          -2.30          Missed
 Dec. 31 2023      -2.03          -1.54          Beat
 Sep. 30 2023      -2.38          -2.88          Missed